RMC-6272

RMC-6272 is a selective, bi-steric mTORC1 kinase inhibitor developed by Revolution Medicines. It is designed to potently inhibit mTORC1 activity while sparing mTORC2, thereby avoiding the hyperglycemia typically associated with pan-mTOR inhibitors. In preclinical models of endometrial carcinoma, particularly those harboring coexistent PTEN loss-of-function and activating PIK3CA mutations, RMC-6272 has demonstrated superior efficacy compared to PI3K or AKT inhibitors by effectively reducing protein translation and inducing G0/G1 cell cycle arrest. It serves as a preclinical tool compound for the clinical-stage candidate RMC-5552.